MediGene AG · LS:A40ESG
MediGene — 9M 2010 Earnings Presentation
14 slides from MediGene's earnings presentation, Nov 12, 2010
Slide 1: Analyst Conference Call 9 Months 2010 Financial Results
Analyst Conference Call 9 Months 2010 Financial Results November 12, 2010 Dr. Frank Mathias, CEO Arnd Christ, CFO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects" expects , "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will", "may" or words
Slide 3: Recent achievements
Recent achievements
Slide 4: Major achievements in first 9 months of 2010
Major achievements in first 9 months of 2010 Succesful conclusion of the phase II clinical trial with EndoTAG™-1 in combination therapy in triple negative breast cancer Further partnerships for marketing Veregen® concluded ((Israel,, Greece and Cyprus, yp , China and South Korea)) Market launc
Slide 5: Financial results 9 months 2010
Financial results 9 months 2010
Slide 6: Total revenue 9M 2010 growing
Total revenue 9M 2010 growing In € million Total revenue Revenue increase mainly driven by Eligard® sales 24% (9M 2010: € 35.3 35 3 mio mio.;; 9M 2009: € 28.6 mio.) 35.3 28.6 9M 2009 9M 2010 Total in market sales of Veregen® Veregen® sales now growing 2010 e: € 6 mio. well 2.0 1.6 0.5 Q1 2010 Q2
Slide 7: EBITDA, net loss 9M 2010
EBITDA, net loss 9M 2010 In € million EBITDA loss Reduction due to • higher revenues 27% 13.1 • lower expenses 9.6 9M 2009 9M 2010 Net loss P iti l iinfluenced Positively fl dbby • derivative financial instruments 15.9 48% 8.2 • foreign exchange gains • increased book value of 9M 2009 9M 2010 Me
Slide 8: Cash flow analysis
Cash flow analysis In € million Development of cash and cash equivalents Cash as of September 30, 2010: € 10.8 mio. 25 2.5 0 0 0.1 Cash flow from operating activities includes payment of € 5 mio. from 10.8 8.2 Astellas SEDA was not used in Q3 2010, no intention of further usage June 30, Operat
Slide 9: Corporate restructuring now completed
Corporate restructuring now completed Right-sizing of business mainly possible as MediGene achieved major milestones in the past months: • EndoTAGTM-1 p phase II trial in TNBC completed p in first half of 2010 • CMC conversion from freeze to spray drying successfully concluded • Simplification of
Slide 10: Outlook
Outlook
Slide 11: Financial outlook for 2010
Financial outlook for 2010 Revenues higher than previous guidance: 47 to 49 million (previously € 44 to 48 million) Transfer of Eligard rights is expected to take place on March 1, 2011 Payments from sale of Eligard-rights Eligard rights to Astellas will be recognized in 2011 EBITDA: € -12
Slide 12: Project Outlook
Project Outlook EndoTAG™-1: Concluding a partnering deal Eligard®: Payment off second and third milestone from f Astellas Veregen®: Increasing revenues expected and additional marketing partnerships to be concluded RhuDex®: Preclinical results 12
Slide 13: Questions & Answers
Questions & Answers Dr. Frank Mathias, CEO A d Ch Arnd Christ, i t CFO
Slide 14: MediGene AG
MediGene AG Lochhamer Straße 11 82152 Planegg / Martinsried, Martinsried Germany Phone: +49 89 85 65 29 00 Fax: +49 89 85 65 29 20 www.medigene.com g